Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591567293> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2591567293 endingPage "552" @default.
- W2591567293 startingPage "552" @default.
- W2591567293 abstract "552 Background: Anti-Epidermal growth factor receptor (EGFR) antibody therapy is expected to be effective in treatment for metastatic colorectal cancer (mCRC) with wild-type KRAS, but for mCRC with mutated KRAS, no salvage treatment has been established. We performed a phase II clinical study on 3rd-line chemotherapy combined bevacizumab with S-1, an oral fluorinated pyrimidine preparation containing a dihydropyrimidine dehydrogenase inhibitor, and bevacizumab for mCRC resistant to oxaliplatin and irinotecan. Methods: Subjects were mCRC patients with mutated KRAS, who showed aggravation even after 2 regimens with oxaliplatin and irinotecan. S-1 (80-120 mg/body) was administered for 4 weeks and withdrawn for 2 weeks. The dose of S-1 was decided according to the subjects’ body surface area. Bevacizumab (5 mg/kg) was administered on Days 1, 15, and 29. This treatment was provided until progression. The primary endpoint was disease control rate (DCR), and secondary endpoints were response rate (RR), median progression free survival (mPFS), overall survival (OS), and adverse event (AE). Results: A total of 31 subjects mutated KRAS were enrolled between August 2009 and July 2011. An independent review committee evaluated antitumor effects in eligible 29 of the 31 subjects in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST). Two subjects in whom antitumor effects could not be evaluated were excluded. The DCR was 69% (95% confidence interval [CI], 49.2-84.7%), RR 0% (95% CI, 0-12.3%), mPFS 3.7 months (95% CI, 2.7-6.5 months), OS 9.0 months (95% CI, 7.5-12.0 months), and the median observation period 9.0 months. In 30 subjects for safety evaluation, the incidence of Grade 3 or greater adverse events was 50%. There was no treatment-related death. Major adverse events were anorexia (Grade 3 or greater, 20%), diarrhea (Grade 3, 10%), and decreased hemoglobin (Grade 3 or greater, 16.7%). Conclusions: The results suggest that 3rd-line chemotherapy combined bevacizumab with S-1 is safe and may delay the progression of mCRC resistant to oxaliplatin and irinotecan with mutated KRAS. Clinical trial information: NCT00974389." @default.
- W2591567293 created "2017-03-03" @default.
- W2591567293 creator A5016333208 @default.
- W2591567293 creator A5021200263 @default.
- W2591567293 creator A5025670670 @default.
- W2591567293 creator A5026657616 @default.
- W2591567293 creator A5031011136 @default.
- W2591567293 creator A5035399792 @default.
- W2591567293 creator A5038183052 @default.
- W2591567293 creator A5040824519 @default.
- W2591567293 creator A5049839257 @default.
- W2591567293 creator A5062565190 @default.
- W2591567293 creator A5068540680 @default.
- W2591567293 creator A5084820122 @default.
- W2591567293 creator A5087398756 @default.
- W2591567293 date "2013-02-01" @default.
- W2591567293 modified "2023-10-03" @default.
- W2591567293 title "A phase II study on third-line chemotherapy combined bevacizumab with S-1 for metastatic colorectal cancer with mutated KRAS: SAVIOR study." @default.
- W2591567293 doi "https://doi.org/10.1200/jco.2013.31.4_suppl.552" @default.
- W2591567293 hasPublicationYear "2013" @default.
- W2591567293 type Work @default.
- W2591567293 sameAs 2591567293 @default.
- W2591567293 citedByCount "0" @default.
- W2591567293 crossrefType "journal-article" @default.
- W2591567293 hasAuthorship W2591567293A5016333208 @default.
- W2591567293 hasAuthorship W2591567293A5021200263 @default.
- W2591567293 hasAuthorship W2591567293A5025670670 @default.
- W2591567293 hasAuthorship W2591567293A5026657616 @default.
- W2591567293 hasAuthorship W2591567293A5031011136 @default.
- W2591567293 hasAuthorship W2591567293A5035399792 @default.
- W2591567293 hasAuthorship W2591567293A5038183052 @default.
- W2591567293 hasAuthorship W2591567293A5040824519 @default.
- W2591567293 hasAuthorship W2591567293A5049839257 @default.
- W2591567293 hasAuthorship W2591567293A5062565190 @default.
- W2591567293 hasAuthorship W2591567293A5068540680 @default.
- W2591567293 hasAuthorship W2591567293A5084820122 @default.
- W2591567293 hasAuthorship W2591567293A5087398756 @default.
- W2591567293 hasConcept C121608353 @default.
- W2591567293 hasConcept C126322002 @default.
- W2591567293 hasConcept C143998085 @default.
- W2591567293 hasConcept C197934379 @default.
- W2591567293 hasConcept C203092338 @default.
- W2591567293 hasConcept C207103383 @default.
- W2591567293 hasConcept C2776694085 @default.
- W2591567293 hasConcept C2777802072 @default.
- W2591567293 hasConcept C2779984678 @default.
- W2591567293 hasConcept C2779998722 @default.
- W2591567293 hasConcept C2780259306 @default.
- W2591567293 hasConcept C2780962732 @default.
- W2591567293 hasConcept C2781187634 @default.
- W2591567293 hasConcept C31760486 @default.
- W2591567293 hasConcept C44249647 @default.
- W2591567293 hasConcept C526805850 @default.
- W2591567293 hasConcept C535046627 @default.
- W2591567293 hasConcept C71924100 @default.
- W2591567293 hasConcept C90924648 @default.
- W2591567293 hasConceptScore W2591567293C121608353 @default.
- W2591567293 hasConceptScore W2591567293C126322002 @default.
- W2591567293 hasConceptScore W2591567293C143998085 @default.
- W2591567293 hasConceptScore W2591567293C197934379 @default.
- W2591567293 hasConceptScore W2591567293C203092338 @default.
- W2591567293 hasConceptScore W2591567293C207103383 @default.
- W2591567293 hasConceptScore W2591567293C2776694085 @default.
- W2591567293 hasConceptScore W2591567293C2777802072 @default.
- W2591567293 hasConceptScore W2591567293C2779984678 @default.
- W2591567293 hasConceptScore W2591567293C2779998722 @default.
- W2591567293 hasConceptScore W2591567293C2780259306 @default.
- W2591567293 hasConceptScore W2591567293C2780962732 @default.
- W2591567293 hasConceptScore W2591567293C2781187634 @default.
- W2591567293 hasConceptScore W2591567293C31760486 @default.
- W2591567293 hasConceptScore W2591567293C44249647 @default.
- W2591567293 hasConceptScore W2591567293C526805850 @default.
- W2591567293 hasConceptScore W2591567293C535046627 @default.
- W2591567293 hasConceptScore W2591567293C71924100 @default.
- W2591567293 hasConceptScore W2591567293C90924648 @default.
- W2591567293 hasIssue "4_suppl" @default.
- W2591567293 hasLocation W25915672931 @default.
- W2591567293 hasOpenAccess W2591567293 @default.
- W2591567293 hasPrimaryLocation W25915672931 @default.
- W2591567293 hasRelatedWork W1958805062 @default.
- W2591567293 hasRelatedWork W1963973664 @default.
- W2591567293 hasRelatedWork W2046962814 @default.
- W2591567293 hasRelatedWork W2051540233 @default.
- W2591567293 hasRelatedWork W2591567293 @default.
- W2591567293 hasRelatedWork W2599877819 @default.
- W2591567293 hasRelatedWork W2617055067 @default.
- W2591567293 hasRelatedWork W2778209820 @default.
- W2591567293 hasRelatedWork W2901178367 @default.
- W2591567293 hasRelatedWork W3003103377 @default.
- W2591567293 hasVolume "31" @default.
- W2591567293 isParatext "false" @default.
- W2591567293 isRetracted "false" @default.
- W2591567293 magId "2591567293" @default.
- W2591567293 workType "article" @default.